Cara Therapeutics, Inc.

Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has completed its merger with Cara Therapeutics. The combined company will focus on developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.

Related tickers: CARA.

Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points. The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst Joseph Stringer downgraded the rating on the stock from Buy to Hold. HC Wainwright analyst Oren Livnat downgraded the rating on the stock from Buy to Neutral. Check out other analyst stock ratings. Needham: Cara Therapeuticssaidafter market close on Wednesday that "the dose-finding Part A portion of the Ph2/3 KOURAGE trial evaluating oral Korsuva (difelikefalin) in Notalgia Parasthetica (NP) failed to show efficacy vs. pbo," Stringer ...Full story available on Benzinga.com

Related tickers: CARA.